@article{604206592e474edc86e18151ad31b5e6,
title = "A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells",
abstract = "The most aggressive and invasive tumor cells often reside in hypoxic microenvironments and rely heavily on rapid anaerobic glycolysis for energy production. This switch from oxidative phosphorylation to glycolysis, along with up-regulation of the glucose transport system, significantly increases the release of lactic acid from cells into the tumor microenvironment. Excess lactate and proton excretion exacerbate extracellular acidification to which cancer cells, but not normal cells, adapt. We have hypothesized that carbonic anhydrases (CAs) play a role in stabilizing both intracellular and extracellular pH to favor cancer progression and metastasis. Here, we show that proton efflux (acidification) using the glycolytic rate assay is dependent on both extracellular pH (pHe) and CA IX expression. Yet, isoform-selective sulfonamide-based inhibitors of CA IX did not alter proton flux, which suggests that the catalytic activity of CA IX is not necessary for this regulation. Other investigators have suggested the CA IX co-operates with the MCT transport family to excrete protons. To test this possibility, we examined the expression patterns of selected ion transporters and show that members of this family are differentially expressed within the molecular subtypes of breast cancer. The most aggressive form of breast cancer, triple-negative breast cancer, appears to co-ordinately express the monocarboxylate transporter 4 (MCT4) and carbonic anhydrase IX (CA IX). This supports a possible mechanism that utilizes the intramolecular H+ shuttle system in CA IX to facilitate proton efflux through MCT4.",
author = "Mboge, {Mam Y.} and Zhijuan Chen and Daniel Khokhar and Alyssa Wolff and Lingbao Ai and Heldermon, {Coy D.} and Murat Bozdag and Fabrizio Carta and Supuran, {Claudiu T.} and Brown, {Kevin D.} and Robert McKenna and Frost, {Christopher J.} and Frost, {Susan C.}",
note = "Funding Information: The authors would like to recognize the exceptional cell culture skills of Xiao Wei Gu. We would also like to thank the Center for Immunology and Transplantation at the University of Florida for access to the Seahorse equipment. This research was financed by the National Institutes of Health, project CA165284 (S.C.F.) and minority supplement CA165284-03S1 (M.Y.M.). Part of this work was performed with assistance of the University of Louisville Genomics Facility and Bioinformatics Core, which was supported by NIH/NIGMS Phase III COBRE P30 GM106396, NIH/NIGMS KY-INBRE P20GM103436, the James Graham Brown Foundation, and user fees. Funding for RNA sequencing was provided under the aegis of the NIH/NIGMS Phase III COBRE P30 GM106396 by the Kentucky Biomedical Research Infrastructure Network (KBRIN) Next Generation Sequencing (NGS) project KBRIN0093 (C.J.F.). Funding Information: M.Y.M., Z.C., D.K., A.W., and L.A. performed experiments. C.D.H. provided oversight for xenograft and PDX animal experiments. M.B., F.C., and C.T.S. provided sulfonamide inhibitors. K.D.B. created the Crispr CA IX knockout cells. C.J.F. performed the statistical analysis and analyzed the RNA seq data. M.Y.M., R.M., and S.C.F. developed the research strategy. M.Y.M. wrote the first draft of the manuscript and participated in its editing. C.J.F., R.M., and S.C.F. provided feedback on the manuscript. C.J.F. and S.C.F. gained financial support for the project. S.C.F. provided oversight for the entire project. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = may,
day = "28",
doi = "10.1042/BCJ20190177",
language = "English (US)",
volume = "476",
pages = "1497--1513",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "10",
}